%0 Journal Article
%A Mai, Elias K
%A Hielscher, Thomas
%A Bertsch, Uta
%A Salwender, Hans J
%A Zweegman, Sonja
%A Raab, Marc S
%A Munder, Markus
%A Pantani, Lucia
%A Mancuso, Katia
%A Brossart, Peter
%A Beksac, Meral
%A Blau, Igor W
%A Dürig, Jan
%A Besemer, Britta
%A Fenk, Roland
%A Reimer, Peter
%A van der Holt, Bronno
%A Hänel, Mathias
%A von Metzler, Ivana
%A Graeven, Ullrich
%A Müller-Tidow, Carsten
%A Boccadoro, Mario
%A Scheid, Christof
%A Dimopoulos, Meletios A
%A Hillengass, Jens
%A Weisel, Katja C
%A Cavo, Michele
%A Sonneveld, Pieter
%A Goldschmidt, Hartmut
%T Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
%J Leukemia
%V 38
%N 3
%@ 0887-6924
%C London
%I Springer Nature
%M DKFZ-2023-02577
%P 640-647
%D 2024
%Z 2024 Mar;38(3):640-647
%X Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38062124
%R 10.1038/s41375-023-02105-6
%U https://inrepo02.dkfz.de/record/285996